cell therapy

January 31, 2023

WATCH: Capricor Data Update From Ongoing HOPE-2 Open Label Extension Trial – Webinar Recording

WATCH: Capricor Data Update From Ongoing HOPE-2 Open Label Extension Trial Capricor Therapeutics recently joined PPMD for a community webinar on January 25, 2023 to present recent data findings from the ongoing HOPE-2 open label…

Learn More

WATCH: Capricor’s HOPE-2 Final 12-Month Data – Webinar Recording

Capricor Therapeutics recently announced positive final 12-month results from the HOPE-2 Trial. HOPE-2 was a randomized, double-blind, placebo-controlled study focused on later-stage Duchenne patients. On June 3, 2020, Capricor joined PPMD for a webinar to…

Learn More

Capricor Announces Positive Top-Line Final Results from HOPE-2 Study

PPMD is excited to learn that Capricor Therapeutics has announced positive top-line 12-month results of the HOPE-2 clinical trial using CAP-1002 to treat non-ambulatory patients with Duchenne. Capricor has reported that the placebo patients in…

Learn More

WATCH: Capricor’s HOPE-2 Interim Analysis – Webinar Recording

On Wednesday, July 17, 2019, Capricor joined Parent Project Muscular Dystrophy for a webinar to update the community on Capricor’s HOPE-2 clinical program, following the company’s announcement of positive results from their interim analysis in…

Learn More

Capricor Announces Positive Results from its Interim Analysis in the HOPE-2 Trial

Capricor Therapeutics has just announced positive results from their interim analysis in the HOPE-2 Trial after placing a voluntary dosing hold earlier this year. Please join PPMD and Capricor as we host a webinar Wednesday,…

Learn More

WATCH: Capricor’s Clinical Program – Webinar Recording

On Wednesday, April 24, 2019, Capricor joined Parent Project Muscular Dystrophy for a webinar to update the community on Capricor’s HOPE2 clinical program. If you missed the live event, the recording can be found below….

Learn More

January 22, 2019

Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA

Capricor Therapeutics announced that it had positive outcomes in its comprehensive multidisciplinary meeting with the FDA regarding development of the company’s novel cell therapy candidate, CAP-1002, after being placed on voluntary hold last month. To…

Learn More

WATCH: HOPE-2 Duchenne Clinical Trial – Webinar Recording with Capricor

Capricor Therapeutics recently joined PPMD for a community webinar update to discuss the HOPE-2 trial. During the webinar, Capricor provided a background of CAP-1002 and its clinical development to date that has led to the…

Learn More

Join Our Mailing List